315 results on '"Currier, Jeffrey R."'
Search Results
2. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
3. Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial
4. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
5. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain
6. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine
7. Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand
8. Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population
9. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
10. Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
11. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
12. Protective Role of NS1-Specific Antibodies in the Immune Response to Dengue Virus Through Antibody-Dependent Cellular Cytotoxicity
13. Next-generation sequencing of 11 HLA loci in a large dengue vaccine cohort from the Philippines
14. 467. Maternal Antibody and Placental Transfer Increases with Hybrid Immunity Against SARS-CoV-2 but Transferred Antibody is Qualitatively Different
15. Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques
16. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
17. Characterization of the cell-mediated immune response to the NIH tetravalent dengue vaccine in an endemic population
18. Soluble NS1 antagonizes IgG- and IgA-mediated monocytic phagocytosis of DENV infected cells
19. Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions
20. Analysis of cell-associated DENV RNA by oligo(dT) primed 5’ capture scRNAseq
21. Analysis of cell-mediated immune responses in support of dengue vaccine development efforts
22. Soluble NS1 antagonizes IgG- and IgA-mediated monocytic phagocytosis of DENV infected cells
23. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN
24. Virologic, clinical, and immunological characteristics of a dengue virus 3 human challenge model
25. Evolution of inflammation and immunity in a dengue virus 1 human infection model
26. Dengue virus downregulates TNFR1- and TLR3-stimulated NF-κB activation by targeting RIPK1
27. mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates
28. Designing the epitope flanking regions for optimal generation of CTL epitopes
29. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals
30. A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model
31. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
32. Evolution of inflammation and immunity in a dengue virus 1 human infection model
33. mRNA-1273 vaccination protects against SARS-CoV-2 elicited lung inflammation in non-human primates
34. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
35. Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection
36. 1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
37. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
38. Immunopathogenesis versus Protection in Dengue Virus Infections
39. Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand.
40. Preparation of Clinical-Grade Recombinant Canarypox-Human Immunodeficiency Virus Vaccine-Loaded Human Dendritic Cells
41. Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections
42. Longitudinal Analysis of Dengue Virus–Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection
43. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
44. Non‐structural protein 1‐specific antibodies directed against Zika virus in humans mediate antibody‐dependent cellular cytotoxicity
45. Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity
46. A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells
47. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
48. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
49. Persistent COVID-19 symptoms minimally impact the development of SARS-CoV-2 specific cellular immunity
50. Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.